Kliniken & Institute … Institute Heidelberger Institut… Groups & Projects Working Groups Data Sharing for Global… Research

ReCoDID

ReCoDID (‘Reconciliation of Cohort data in Infectious Diseases’), is a  consortium bringing ogether a multidisciplinary team from four continents to fast track the research response to viruses and other pathogens by facilitating data and sample sharing between infectious disease cohort studies.

ReCoDID Website

Duration: 2019-2023

Funding: Funded by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 825746 and the Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG) under Grant Agreement N.01886-000.

Team members at HIGH: Till Bärnighausen, Heather Hufstedler, Lauren Maxwell, Johannes Boucsein, Kerstin Rosenberger, Frank Tobian, Thomas Jaenisch

Partner Institutions: EMBL-EBI; Erasmus MC; UMC Utrecht; Aix Marseille; DTU; McMaster; McGill; University of British Colombia; UC Berkeley; Universidad Industrial Santander; Sustainable Sciences Institute; Institut Pasteur de DakarOswaldo Cruz Institute (IOC)

Citation for related publications: de Jong VMT, Moons KGM, Riley RD, et al. Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example. Res Synth Methods. 2020;11(2):148-168. doi:10.1002/jrsm.1384

Link to publication: Res Synth Methods. 2020 Mar;11(2):148-168. doi: 10.1002/jrsm.1384

 

 

ECRAID Plan

ECRAID Plan is a European-wide initiative with the goal of establishing a sustainable clinical research network to facilitate cross-national collaborations and platform clinical trails.  ECRAID will advance Europe's response to infectious diseases, whether endemic or emerging. ECRAID represents a major cross-national investment in public health and scientific advancement on behalf of the European Comission's Horizon 2020 Programme.

ECRAID Website

Duration: 2019-2020

Funding: ECRAID-Plan is funded by the European Commission under Grant Agreement 825715

Team members at HIGH: Lauren Maxwell, Kerstin Rosenberger, Thomas Jaenisch

ZIKV IPD-MA

The ZIKV Individual Participant Data (IPD) Consortium to identify, collect and synthesise IPD from longitudinal studies of pregnant women that measure ZIKV infection during pregnancy and fetal, infant or child outcomes.  The ZIKV IPD-MA includes 46 partner studies from 28 countries or territories, representing longitudinal data on 20,000 maternal-infant pairs.

ZIKV IPD-MA Website

Duration: 2019-2022

Funding: Funded by DfID-Wellcome Trust USAID

Team members at HIGH: Lauren Maxwell, Kerstin Rosenberger, Frank Tobian, Thomas Jaenisch, Annelies Wilder-Smith

Partner Institutions: WHO - Department of Sexual and Reproductive Health and Research; PAHO; US-CDCNIH/NIAIDZIKAlliance; ZIKAction; ZikaPLAN; INSERM; Fiocruz; Ministry of Health, Colombia; Stanford University; Tulane University

Citation for related publications: Wilder-Smith A, Wei Y, Araújo TVB, et al. Understanding the relation between Zika virus infection during pregnancy and adverse fetal, infant and child outcomes: a protocol for a systematic review and individual participant data meta-analysis of longitudinal studies of pregnant women and their infants and children. BMJ Open. 2019;9(6):e026092. Published 2019 Jun 18. doi:10.1136/bmjopen-2018-026092

Link to publication: https://pubmed.ncbi.nlm.nih.gov/31217315/

Short description of each publication: Zika virus (ZIKV) infection during pregnancy is a known cause of microcephaly and other congenital and developmental anomalies. In the absence of a ZIKV vaccine or prophylactics, principal investigators (PIs) and international leaders in ZIKV research have formed the ZIKV Individual Participant Data (IPD) Consortium to identify, collect and synthesise IPD from longitudinal studies of pregnant women that measure ZIKV infection during pregnancy and fetal, infant or child outcomes.

 

 

Risk in the time of ZIKV

The Risk in the time of ZIKV explores community member preferences for communicating risk during pregnancy in the presence of uncertainty in both Zika diagnostics and the absolute risk of adverse pregnancy outcomes or longer term developmental outcomes at 7 sites in three countries.

Risk in the time of ZIKV Website

Duration: 2019-2022

Funding: Funded by the DfID-Wellcome Trust

Team members at HIGH: Lauren Maxwell

Partner Institutions: Universidad Industrial de SantanderFiocruz Universidad de Puerto Rico; Ministerio de Salud, Colombia; IPESQ

 

 

EN